Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019

Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019. Business WireJuly 10, 2019, 10:45 AM UTC. Merck (MRK), known as MSD outside the United States and Canada, announced today that the results from studies evaluating MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), are scheduled to be presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) taking place July 21 – 24, 2019 in Mexico City. “Building upon our proud heritage in HIV, we are excited to share these latest findings for MK-8591,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Tolerability, safety and efficacy of MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine and lamivudine through 24 weeks in treatment-naïve adults with HIV-1 infection.

First found on: www.benzinga.com And then on: 2 other references